The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor shot. Moderna said its own vaccine, dubbed ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast. Back in ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Embattled CytoDyn and key ex-executives must face an investor lawsuit claiming the company knowingly misled shareholders ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in ...

Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the ...

Turnstone Biologics has limped to the exit. Xoma Royalty is buying Turnstone for less than $8 million, marking a low-profile ...

Cosmo Pharmaceuticals aims to make the colonoscopy a little more up close and personal, for providers anyway, by connecting ...

Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Massachusetts, in ...

Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 ...